MXCT MaxCyte, Inc.
Healthcare$1.00-3.85%ClosedMarket Cap: $107.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.66
P/S
3.45
EV/EBITDA
-3.17
DCF Value
$-3.05
FCF Yield
-26.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.7%
Operating Margin
-119.7%
Net Margin
-121.2%
ROE
-22.0%
ROA
-20.1%
ROIC
-20.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $9.7M | 73.2% | $-6.2M | $-4.8M | $— | — |
| Q4 null | $7.3M | 77.9% | $-7.7M | $-9.6M | $— | — |
| FY null | $33.0M | 81.2% | $-45.3M | $-44.6M | $— | — |
| Q3 null | $6.8M | 92.4% | $-10.6M | $-12.4M | $— | — |
| Q2 null | $8.5M | 82.1% | $-14.2M | $-12.4M | $— | — |
| Q1 null | $10.4M | 85.6% | $-12.3M | $-10.3M | $— | — |
| Q4 null | $8.7M | 73.8% | $-12.9M | $-10.6M | $— | — |
| FY null | $38.6M | 81.6% | $-51.2M | $-41.1M | $— | — |
| Q3 null | $8.2M | 76.4% | $-14.1M | $-11.6M | $— | — |
| Q2 null | $10.4M | 85.7% | $-12.0M | $-9.4M | $— | — |
| Q1 null | $11.3M | 87.6% | $-12.3M | $-9.5M | $— | — |
| Q4 2023 | $15.7M | 90.0% | $-8.1M | $-5.3M | $-0.05 | — |